Artrya Limited (AYA) Fair Value & Analysis
Healthcare · AU · Market cap A$774M
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Share price +11.8% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.6289 – A$5.23 · fair‑value band A$0.4400 – A$0.7400 · the A$5.16 price screens above the A$0.5900 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Artrya Limited (AYA) currently trades at A$5.16, while our model-based Fair Value estimate is A$0.5900 — implying the stock looks roughly 88.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$29.0K. Revenue grew 7.7% year over year. It earns a return on equity of -37.9%. The balance sheet holds a net cash position of A$10.7M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Artrya Limited reported revenue of A$28.0K in FY2025 versus A$0 in FY2021. Reported net income was −A$16.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $86.03 | $54.47 | -37% |
| M3, Inc MTHRY | $5.20 | $5.32 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Artrya Limited (AYA) undervalued?
What is the fair value of AYA?
What is the quality score of AYA?
What is the revenue of Artrya Limited (AYA)?
What is the net profit margin of AYA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.